There is potential that a marker of myocardial injury such as troponin can add to the value of existing indicators and biomarkers of cardiovascular disease risk.
Ischaemia modified albumin (IMA) has been used as a marker of myocardial ischaemia but little is known about its production during ischaemia of other tissues.
To evaluate the effect of medetomidine butorphanol sedation on serum cardiac troponin I (cTnI) concentration, a marker of myocardial ischemia and injury, in healthy dogs undergoing pre surgical radiographs for orthopedic procedures.
This study was designed to investigate whether the serum concentration of the carboxy-terminal propeptide of procollagen type I (PIP), a marker of myocardial fibrosis, is related to changes of the ventricular filling dynamics in patients with early type 2 diabetes mellitus (T2DM).
Study Objective: To assess the utility of troponin I, the only molecular marker of myocardial injury not expressed in regenerating muscle, in diagnosing perioperative myocardial infarction (MI) in the setting of orthopedic surgery where false elevations in creatine kinase MB isoenzymes (CKMB) are known to occur.
Troponin is a marker of myocardial stress/ischemia.
Moreover, lymphocytes may provide a surrogate marker of myocardial GRK2 in these patients.
Distinct changes were also noted in troponin T, a marker of myocardial damage.
Aortic peak systolic blood flow velocity (Vmax) was used as a marker of myocardial contractility.
Troponin is a particularly sensitive and specific marker of myocardial ischemia as it is only released from damaged myocardium unlike CK and lactic dehydrogenase (LDH).
The central consideration in the interpretation of an elevated serum cTn is that it is a marker of myocardial damage, but on its own it does not determine the etiology of the damage.
